GLP-1 drugs show promise in treating PMOS hormonal disorder

Research indicates that GLP-1 obesity medications may show promise in treating Polyendocrine Metabolic Ovarian Syndrome (PMOS), a hormonal condition affecting approximately one in eight women globally. Studies led by Dr. Melanie Cree suggest these drugs may improve insulin resistance, hormone balance, and ovulation, in addition to promoting weight loss.

PMOS, formerly known as polycystic ovary syndrome (PCOS), was renamed earlier this year to shift clinical focus away from ovaries and cysts. The condition is often difficult to diagnose due to overlapping symptoms such as irregular periods, weight gain, acne, and excessive hair growth. The World Health Organization estimates that up to 70% of women with the condition remain undiagnosed.

In Jersey, a new nurse-led screening service is scheduled to launch this autumn. The clinic will provide a comprehensive service, including ultrasound scans and endometrial biopsies, to improve early identification of PMOS and its associated risks, such as type 2 diabetes and endometrial cancer.